Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

• Status: Completed
• Trial end date: 2023-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Atea Pharmaceuticals, Inc.
• Treatments: Moxifloxacin

Criteria

Inclusion Criteria:

• Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug

• Females must have a negative pregnancy test at Screening and prior to dosing

• Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2

• Willing to comply with the study requirements and to provide written informed consent

Exclusion Criteria:

• Pregnant or breastfeeding

• Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19

• Abuse of alcohol or drugs

• Use of other investigational drugs within 28 days of dosing

• Other clinically significant medical conditions or laboratory abnormalities